Lee Financial’s Galectin Therapeutics GALT Stock Holding History

Lee Financial’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25	Closed	–	–	801
2018 Q1	$0	Buy	+25	New	+$116	﹤0.01%	756

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EGI

EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Lee Financial's GALT Position: Q2 2018 in Review

Lee Financial sold out of Galectin Therapeutics (GALT) in Q2 2018, closing a stake of 25 shares.

Lee Financial first reported a position in GALT in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 69 funds tracked by Wall St. Rank hold GALT as of Q2 2018.

Lee Financial reported no remaining Galectin Therapeutics position as of Q2 2018 after selling out during the quarter.
Lee Financial sold 25 Galectin Therapeutics shares in Q2 2018.
Lee Financial first reported a position in Galectin Therapeutics in Q1 2018 and held it in 1 quarter.
Lee Financial's Galectin Therapeutics position peaked at $0 in Q1 2018.
69 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2018.

Based on Lee Financial's 13F filing for Q2 2018, filed 14 Aug 2018.